Literature DB >> 11260085

Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility.

C D Bolan1, R W Childs, J L Procter, A J Barrett, S F Leitman.   

Abstract

Immune haemolysis as a result of minor ABO incompatibility is an underappreciated complication of haematopoietic transplantation. The increased lymphoid content of peripheral blood stem cell (PBSC) transplants may increase the incidence and severity of this event. We observed massive immune haemolysis in 3 out of 10 consecutive patients undergoing HLA-identical, related-donor PBSC transplants with minor ABO incompatibility. Non-ablative conditioning had been given in 9 of these 10 cases, including two with haemolysis. Cyclosporin alone was used as prophylaxis against graft-vs.-host disease (GVHD). Catastrophic haemolysis of 78% of the circulating red cell mass led to anoxic death in the first case seen, but severe consequences were avoided by early, vigorous donor-compatible red cell transfusions in the subsequent two cases. Haemolysis began 7-11 d after PBSC infusion and all patients with haemolysis had a positive direct antiglobulin test (DAT), with eluate reactivity against the relevant recipient antigen. However, neither the intensity of the DAT, the donor isohaemagglutinin titre, nor other factors could reliably be used to predict the occurrence of haemolysis. Our data indicate that haemolysis may be frequent and severe after transplantation of minor ABO-incompatible PBSCs when utilizing cyclosporin alone to prevent GVHD. Meticulous clinical monitoring and early, vigorous donor-compatible red cell transfusions should be practiced in all instances.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260085     DOI: 10.1046/j.1365-2141.2001.02587.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

Authors:  C K Brierley; T J Littlewood; A J Peniket; R Gregg; J Ward; A Clark; A Parker; R Malladi; P Medd
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

2.  ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation.

Authors:  Aaron C Logan; Zhiyu Wang; Kamran Alimoghaddam; Ruby M Wong; Tze Lai; Robert S Negrin; Carl Grumet; Brent R Logan; Mei-Jie Zhang; Stephen R Spellman; Stephanie J Lee; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-05       Impact factor: 5.742

3.  Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source.

Authors:  Sharat Damodar; Ryan Shanley; Margaret MacMillan; Celalettin Ustun; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2017-02-14       Impact factor: 5.742

4.  Passenger Lymphocyte Syndrome and Autoimmune Hypothyroidism Following Hematopoietic Stem Cell Transplantation.

Authors:  Denis F Noubouossie; Mohammed I A Zaanona; Luciano J Costa; Huy P Pham; Marisa B Marques; Antonio Di Stasi
Journal:  Case Reports Immunol       Date:  2022-06-23

Review 5.  ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Nina Worel
Journal:  Transfus Med Hemother       Date:  2015-10-29       Impact factor: 3.747

6.  The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation.

Authors:  Zejing Wang; Mohamed L Sorror; Wendy Leisenring; Gary Schoch; David G Maloney; Brenda M Sandmaier; Rainer Storb
Journal:  Br J Haematol       Date:  2010-01-11       Impact factor: 6.998

7.  IgM anti-recipient ABO antibodies predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Authors:  Yoshitaka Zaimoku; Akiyoshi Takami; Hidehiro Sato; Maki Utsumi; Shinji Nakao
Journal:  Int J Hematol       Date:  2013-05-10       Impact factor: 2.490

Review 8.  Non-myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Nonniekaye Shelburne; Margaret Bevans
Journal:  Semin Oncol Nurs       Date:  2009-05       Impact factor: 2.315

9.  Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993-2010): factors that predict intensity and time to transfusion independence.

Authors:  Linda M Griffith; Mark VanRaden; A John Barrett; Richard W Childs; Daniel H Fowler; Elizabeth M Kang; John F Tisdale; Harvey G Klein; David F Stroncek
Journal:  Transfusion       Date:  2018-10-26       Impact factor: 3.157

Review 10.  Post-hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics.

Authors:  Yazan Migdady; Yifan Pang; Shelley S Kalsi; Richard Childs; Sally Arai
Journal:  Blood Adv       Date:  2022-04-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.